Real-world evidence: Flatiron Electronic Health Record Database study of EGFR TKIs
Erlotinib was the most widely prescribed first-line therapy for EGFR Mut+ NSCLC in this study, with similar efficacy observed for erlotinib- and afatinib-treated patients. The efficacy of EGFR TKIs observed in clinical studies was reflected in the real world setting.1
EGFR mutation test rate1
Rates of EGFR mutation testing increased from 2011until 2016.
Usage frequency of different first-line therapies1
Erlotinib was the most widely prescribed therapy for first-line treatment of EGFR Mut+ NSCLC.
Time to next treatment1
Patients receiving erlotinib or afatinib had longer time to next treatment than those receiving non-EGFR TKI therapy.
*Defined as all non-EGFR TKI treatments including chemotherapy and bevacizumab TTNT = time to next treatment
There were no significant differences in overall survival by treatment group.
*Defined as all non-EGFR TKI treatments including chemotherapy and bevacizumab